August 1, 2023Thrombosis and Haemostasis
A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer
View Full Paper
Ask AI
Bookmark
Share
Key result
Text contains only journal editorial board information with no clinical study data.
Why the study?
Anticoagulation for cancer-associated venous thromboembolism is associated with bleeding complications, but risk factor data are limited and current models lack accuracy.
Can a novel risk prediction score accurately predict clinically significant bleeding in patients anticoagulated for cancer-associated venous thromboembolism?
Population
15,749 patients with Ca-VTE initiating anticoagulant treatment
Design
Retrospective cohort study
Follow-up
Up to 180 days
Authors
Discussion
Loading...
Member takes
Implication
May support bleeding risk stratification in cancer-associated VTE; hypothesis-generating pending external validation.
Structured PICO
Can a novel risk prediction score accurately predict clinically significant bleeding in patients anticoagulated for cancer-associated venous thromboembolism?
P
Population
15,749 patients with active cancer and first venous thromboembolism (Ca-VTE) initiating anticoagulant treatment, from the UK Clinical Practice Research Datalink (2008-2020).
I
Intervention
Development of a novel risk prediction score for clinically significant bleeding
O
Outcome
Clinically significant bleeding (composite of major bleeding and clinically relevant nonmajor bleeding requiring hospitalization [CRNMB-H]) up to 180 dayssafety
A novel risk score using clinical predictors and cancer type provides moderate discrimination (C-statistic 0.70) for predicting 6-month significant bleeding in patients anticoagulated for cancer-associated VTE.
Cite This Study
Cohen et al. (2023) studied Venous Thromboembolism with Active Cancer. The provided text contains only journal editorial board information and no clinical study data.
View Full Paper
Ask AI
Bookmark
Share